Literature DB >> 27928426

Treatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trial.

Kirill Vladimirovich Kosilov1, Sergey Loparev2, Irina Kuzina3, Olga Shakirova3, Nataliya Zhuravskaya3, Alexandra Lobodenko3.   

Abstract

AIM: The aim of this work was to study the factors affecting the stability of working patients in antimuscarinic (AM) drug treatment.
BACKGROUND: The prevalence of urge urinary incontinence (UUI) is an average of between 8.2% and 16.0% of the population. UUI is a condition that adversely affects the health-related quality of life. The first-line therapy in managing UUI is AM treatment.
METHODS: In 1006 patients between 18 and 60 years old (627 women, 379 men, mean age 69.4) who received AM treatment for one year, the possible demographic, socioeconomic and health factors influencing compliance were studied. Also, the functional state of the lower urinary tract (LUT) was studied in this randomized, prospective survey. The study instruments were the documents of employers, tax offices, outpatient records, OABq-SF (overactive bladder - short form) questionnaires, MOS SF-36 (Medical Outcomes Study short form-36), voiding charts, and uroflowmetry data.
RESULTS: The compliance to AM treatment within 6 months was retained in 49.5% patients; during the year, in 32.3% of patients. The average time for reaching the 30-day break in taking trospium was 194 days. In the course of the experiment it was revealed that compliance to AM treatment was significantly higher in patients taking solifenacin and trospium in high dosages (p ⩽ 0.01, p ⩽ 0.05), suffering from severe symptoms of urgency (p ⩽ 0.01), and having a low level of side effects (p ⩽ 0.01). A satisfactory level of compliance is characteristic of patients with a high level of monthly and annual income (p ⩽ 0.01, p ⩽ 0.01), a low percentage of expenses to AM (p ⩽ 0.05), and rarely changing employers (p ⩽ 0.05). In addition, the compliance to treatment is higher in older adults (p ⩽ 0.05), living in the urban district (p ⩽ 0.01), and working in educational (p ⩽ 0.05) and health (p ⩽ 0.01) institutions, having a high level of the indices of Social Functioning (p ⩽ 0.05), Role-Emotional (p ⩽ 0.05), and Mental Health (p ⩽ 0.01).
CONCLUSION: As a result of this study, under the control of the objective functional state of LUT, the influence of various factors on the patients' stability in the treatment with AM drugs was revealed.

Entities:  

Keywords:  adherence; antimuscarinic; lower urinary tract; urinary incontinence; working persons

Year:  2016        PMID: 27928426      PMCID: PMC5131742          DOI: 10.1177/1756287216652030

Source DB:  PubMed          Journal:  Ther Adv Urol        ISSN: 1756-2872


  30 in total

1.  Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies.

Authors:  Werner Schäfer; Paul Abrams; Limin Liao; Anders Mattiasson; Francesco Pesce; Anders Spangberg; Arthur M Sterling; Norman R Zinner; Philip van Kerrebroeck
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

2.  An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF.

Authors:  Karin S Coyne; Christine L Thompson; Jin-Shei Lai; Chris C Sexton
Journal:  Neurourol Urodyn       Date:  2014-01-13       Impact factor: 2.696

3.  What is the value of medication adherence?

Authors:  Sarah Clifford; Karin S Coyne
Journal:  J Manag Care Spec Pharm       Date:  2014-07

4.  Additional correction of OAB symptoms by two anti-muscarinics for men over 50 years old with residual symptoms of moderate prostatic obstruction after treatment with Tamsulosin.

Authors:  Kirill Kosilov; Sergey Loparev; Marina Ivanovskaya; Liliya Kosilova
Journal:  Aging Male       Date:  2014-08-19       Impact factor: 5.892

5.  Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage.

Authors:  M Horstmann; T Schaefer; Y Aguilar; A Stenzl; K D Sievert
Journal:  Neurourol Urodyn       Date:  2006       Impact factor: 2.696

6.  Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder.

Authors:  Michael B Chancellor; Kristen Migliaccio-Walle; Thomas J Bramley; Sham L Chaudhari; Catherine Corbell; Denise Globe
Journal:  Clin Ther       Date:  2013-10-03       Impact factor: 3.393

7.  The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL.

Authors:  Karin S Coyne; Chris C Sexton; Jill A Bell; Christine L Thompson; Roger Dmochowski; Tamara Bavendam; Chieh-I Chen; J Quentin Clemens
Journal:  Neurourol Urodyn       Date:  2012-07-27       Impact factor: 2.696

8.  Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database.

Authors:  Siri A Mauseth; Svetlana Skurtveit; Olav Spigset
Journal:  Acta Obstet Gynecol Scand       Date:  2013-07-11       Impact factor: 3.636

9.  Patient-reported reasons for discontinuing overactive bladder medication.

Authors:  Joshua S Benner; Michael B Nichol; Eric S Rovner; Zhanna Jumadilova; Jose Alvir; Mohamed Hussein; Kristina Fanning; Jeffrey N Trocio; Linda Brubaker
Journal:  BJU Int       Date:  2009-11-12       Impact factor: 5.588

10.  Factors affecting therapeutic compliance: A review from the patient's perspective.

Authors:  Jing Jin; Grant Edward Sklar; Vernon Min Sen Oh; Shu Chuen Li
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

View more
  4 in total

1.  CUA guideline on adult overactive bladder.

Authors:  Jacques Corcos; Mikolaj Przydacz; Lysanne Campeau; Gary Gray; Duane Hickling; Christiane Honeine; Sidney B Radomski; Lynn Stothers; Adrian Wagg; Frcp Lond
Journal:  Can Urol Assoc J       Date:  2017-05-09       Impact factor: 1.862

Review 2.  Nonbiologic factors that impact management in women with urinary incontinence: review of the literature and findings from a National Institute of Diabetes and Digestive and Kidney Diseases workshop.

Authors:  Jenna M Norton; Jennifer L Dodson; Diane K Newman; Rebecca G Rogers; Andrea D Fairman; Helen L Coons; Robert A Star; Tamara G Bavendam
Journal:  Int Urogynecol J       Date:  2017-07-03       Impact factor: 2.894

3.  Influence of current state of executive function and working memory on adherence to antimuscarinic therapy in older women with OAB.

Authors:  Kirill Kosilov; Irina Kuzina; Vladimir Kuznetsov; Ekaterina Kosilova
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2019-07-27

4.  Efficacy of a combination of dutasteride, tadalafil, and solifenacin in the treatment of previously unsuccessful patients.

Authors:  Kirill Kosilov; Irina Kuzina; Vladimir Kuznetsov; Olga Barabash; Ekaterina Fedorishcheva
Journal:  Asian J Urol       Date:  2021-04-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.